Comparative Study of Dorzol Eye Drops, 20 mg/ml Versus Trusopt® Eye Drops, 20 mg/ml

Inclusion Criteria: * Females or males in the age bracket of 18 to 75 years. * Established stage I and II primary open-angle glaucoma in one or both eyes. * IOP = 21-27 mm Hg (by Goldmann applanation tonometry). * Visual acuity 0.3 or better on the tested eye. * Patients who have signed an informed consent to participate in the study. * For females of child-bearing potential - a negative pregnancy test and consent to use reliable contraception methods throughout the study. Exclusion Criteria: * Contraindications or hypersensitivity to the active ingredient (dorzolamide) or excipients. * The only eye. * Visual acuity ˂ 0.3 after correction. * An active infectious inflammatory process on the tested eye within 3 months prior to pre-study medical examination. * Pronounced visual field defects (III and IV stage open-angle glaucoma). * IOP ˃ 27 mm Hg or ˂ 21 mm Hg as at the IOP measuring at 10.00 a.m. (±1 h) in any of the eyes on the screening visit day. * Closed or nearly closed anterior chamber angle (ACA) or history of acute angle close. * Surgical and laser eye interventions over the last 3 months. * Manifest ocular media opacification hindering the treatment efficacy evaluation. * Other eye diseases that may affect dynamics of the parameters used for the treatment efficacy evaluation. * Inflammatory conditions of the eye and appendages (blepharitis, conjunctivitis). * Chronic kidney disease (creatinine clearance ˂ 30 mL/min). * Hyperchloremic acidosis. * Concomitant adminis…